Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Overweight and obesity management | Guidance (NG246) - Medicines and surgery
Njalsson, R., Ristoff, E., Carlsson, K., Winkler, A., Larsson, A
Safety in patients with existing mild-moderate liver disease Correlation between weight loss and estimated liver fat reduction TRIUMPH-2 (Ongoing, Expected 2026) Primary Endpoints: Weight loss in diabetic patients HbA1c reduction Secondary Endpoints (Liver): Liver enzymes Metabolic markers Diabetic Population Note: Higher prevalence of MASLD/NASH (~40-50%), so liver benefits particularly important in this group
Neurotoxic reactive astrocytes drive neuronal death after retinal injury
The recommended duration of Semaglutide GLP-1 treatment is typically determined by the prescribing healthcare provider
TRIUMPH-1 is complete, and several other Phase 3 trials have now reported topline results
